Anaptysbio (ANAB) Net Income towards Common Stockholders Growth (1y) (2017 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Net Income towards Common Stockholders Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -12.04% |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 95.87% |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - | -34.47% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -34.47% |
| Dec 31, 2025 | 512.28% |
| Sep 30, 2025 | 146.00% |
| Jun 30, 2025 | 17.21% |
| Mar 31, 2025 | 10.49% |
| Dec 31, 2024 | 209.22% |
| Sep 30, 2024 | 11.95% |
| Jun 30, 2024 | -17.10% |
| Mar 31, 2024 | -10.07% |
| Dec 31, 2023 | 64.52% |
| Sep 30, 2023 | -36.30% |
| Jun 30, 2023 | -49.28% |
| Mar 31, 2023 | -27.09% |
| Dec 31, 2022 | 28.80% |
| Sep 30, 2022 | -308.58% |
| Jun 30, 2022 | -6,121.91% |
| Mar 31, 2022 | -72.89% |
| Dec 31, 2021 | -192.40% |
| Sep 30, 2021 | 71.81% |
| Jun 30, 2021 | 98.01% |